LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Lifevantage Corp

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026

$5.98−0.02 (-0.33%)

Close on Oct 19, 2026

Market cap: $74.97M
P/E (TTM): 15.0
Dividend yield: 3.09%

Fundamental chart

Pick a measure to chart its full history

$182.59MFY2026, +2.7% a year since FY2012

Where these numbers come from

Parsed from the XBRL in Lifevantage's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-7 reverse split on Oct 19, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LFVN.

Revenue growth-20.1% · median 0.9%

Gross margin77.6% · median 73.2%

Operating margin3.3% · median 4.2%

Net margin2.8% · median -1.6%

Company	Revenue	Growth
NATR	$492.02M	+6.8%
LGND	$290.54M	+54.9%
AMRN	$186.23M	-15.1%
LFVN	$182.59M	-20.1%
MTEX	$107.36M	-5.0%
PRE	–	–

Company

Next earnings (est.): Nov 3, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 223
Held by institutions: 47.2%
Auditor: Deloitte & Touche LLP
SEC CIK: 849146

Advertisement
300 × 250